{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T02:15:55Z","timestamp":1775700955350,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Omadacycline is a novel aminomethylcycline tetracycline antimicrobial that was approved for the treatment of community-associated bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in 2018. Omadacycline has demonstrated a high degree of in vitro activity towards Clostridioides difficile and previous data have hypothesized that use of omadacycline for CABP or ABSSSI may decrease the risk of C. difficile infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the in vitro antimicrobial activity of omadacycline versus commonly used antimicrobials for the approved indications of use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We compared the antimicrobial activity of eight antimicrobials approved for CABP and ABSSSI against omadacycline by agar dilution on 200 clinically relevant contemporary C. difficile isolates representing local and national prevalent strain types.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The in vitro omadacycline geometric mean MIC was 0.07 mg\/L. Ceftriaxone resistance was noted in &amp;gt;50% of all isolates tested. The epidemic strain group, identified as restriction endonuclease analysis (REA) group BI, was commonly resistant to azithromycin (92%), moxifloxacin (86%) and clindamycin (78%). REA group DH strains had an elevated trimethoprim\/sulfamethoxazole geometric mean MIC of 17.30 mg\/L compared with the geometric mean MIC of 8.14 mg\/L noted in all other isolates. In the REA group BK isolates that had a doxycycline MIC of \u22652 mg\/L, the omadacycline MIC was &amp;lt;0.5 mg\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among 200 contemporary C. difficile isolates, there were no notable elevations in the in vitro omadacycline MIC, indicating a high level of activity towards C. difficile in comparison with commonly used antimicrobials for CABP and ABSSSI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad170","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T13:32:21Z","timestamp":1686317541000},"page":"1779-1784","source":"Crossref","is-referenced-by-count":6,"title":["Antimicrobial susceptibility of <i>Clostridioides difficile<\/i> to omadacycline and comparator antimicrobials"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-9316","authenticated-orcid":false,"given":"Andrew M","family":"Skinner","sequence":"first","affiliation":[{"name":"Department of Medicine, Loyola University Medical Center , Maywood, IL , USA"},{"name":"Research Section, Infection Diseases Section, Edward Hines Jr. VA Hospital , Hines, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurica A","family":"Petrella","sequence":"additional","affiliation":[{"name":"Research Section, Infection Diseases Section, Edward Hines Jr. VA Hospital , Hines, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Cheknis","sequence":"additional","affiliation":[{"name":"Research Section, Infection Diseases Section, Edward Hines Jr. VA Hospital , Hines, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9548-229X","authenticated-orcid":false,"given":"Stuart","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Loyola University Medical Center , Maywood, IL , USA"},{"name":"Research Section, Infection Diseases Section, Edward Hines Jr. VA Hospital , Hines, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"2023070504555327600_dkad170-B1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/cid\/ciaa124","article-title":"Antibiotic prescribing choices and their comparative C. difficile infection risks: a longitudinal case-cohort study","volume":"72","author":"Brown","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023070504555327600_dkad170-B2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/AAC.01820-15","article-title":"Fluoroquinolone and macrolide exposure predict Clostridium difficile infection with the highly fluoroquinolone- and macrolide-resistant epidemic C. difficile strain BI\/NAP1\/027","volume":"60","author":"Wieczorkiewicz","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070504555327600_dkad170-B3","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJM199911253412203","article-title":"Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals","volume":"341","author":"Johnson","year":"1999","journal-title":"N Engl J Med"},{"key":"2023070504555327600_dkad170-B4","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/dkt477","article-title":"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis","volume":"69","author":"Slimings","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2023070504555327600_dkad170-B5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/cix833","article-title":"Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis","volume":"66","author":"Tariq","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"2023070504555327600_dkad170-B6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2023070504555327600_dkad170-B7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14740338.2015.997206","article-title":"Tigecycline: a critical safety review","volume":"14","author":"Kaewpoowat","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"2023070504555327600_dkad170-B8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/antibiotics5040032","article-title":"The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline-binding site on the bacterial ribosome","volume":"5","author":"Heidrich","year":"2016","journal-title":"Antibiotics (Basel)"},{"issue":"Suppl 1","key":"2023070504555327600_dkad170-B9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/cid\/ciz394","article-title":"Omadacycline: a modernized tetracycline","volume":"69","author":"Gallagher","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023070504555327600_dkad170-B10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00522-20","article-title":"In vitro activity of omadacycline, a new tetracycline analog, and comparators against Clostridioides difficile","volume":"64","author":"Begum","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070504555327600_dkad170-B11","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01440-21","article-title":"In vitro activity of omadacycline and five comparators against contemporary ribotypes of Clostridioides difficile in Stockholm, Sweden","volume":"9","author":"Camporeale","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2023070504555327600_dkad170-B12","author":"Centers for Disease Control and Prevention","year":"2017."},{"key":"2023070504555327600_dkad170-B13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1017\/ice.2014.89","article-title":"Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort study","volume":"36","author":"Kociolek","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023070504555327600_dkad170-B14","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1128\/jcm.31.7.1870-1875.1993","article-title":"Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems","volume":"31","author":"Clabots","year":"1993","journal-title":"J Clin Microbiol"},{"key":"2023070504555327600_dkad170-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anaerobe.2018.07.004","article-title":"Correlation between restriction endonuclease analysis and PCR ribotyping for the identification of Clostridioides (Clostridium) difficile clinical strains","volume":"54","author":"Kociolek","year":"2018","journal-title":"Anaerobe"},{"key":"2023070504555327600_dkad170-B16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.anaerobe.2014.04.005","article-title":"International typing study of Clostridium difficile","volume":"28","author":"Manzo","year":"2014","journal-title":"Anaerobe"},{"key":"2023070504555327600_dkad170-B17","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2023070504555327600_dkad170-B18","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023070504555327600_dkad170-B19","volume-title":"Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard\u2014Ninth Edition: M11","author":"CLSI","year":"2018"},{"key":"2023070504555327600_dkad170-B20","author":"pandas development team","year":"2020"},{"key":"2023070504555327600_dkad170-B21","first-page":"51","author":"McKinney"},{"key":"2023070504555327600_dkad170-B22","volume-title":"Python 3 Reference Manual","author":"Van Rossum","year":"2009"},{"key":"2023070504555327600_dkad170-B23","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u201430th Edition: M100","author":"CLSI","year":"2020"},{"key":"2023070504555327600_dkad170-B24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00047-18","article-title":"In vitro activities of omadacycline and comparators against anaerobic bacteria","volume":"62","author":"Stapert","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070504555327600_dkad170-B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkw385","article-title":"Role of cephalosporins in the era of Clostridium difficile infection","volume":"72","author":"Wilcox","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023070504555327600_dkad170-B26","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02790-18","article-title":"A role for tetracycline selection in recent evolution of agriculture-associated Clostridium difficile PCR ribotype 078","volume":"10","author":"Dingle","year":"2019","journal-title":"MBio"},{"key":"2023070504555327600_dkad170-B27","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/JCM.02446-10","article-title":"Comparison of strain typing results for Clostridium difficile isolates from North America","volume":"49","author":"Tenover","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2023070504555327600_dkad170-B28","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1099\/00221287-136-7-1343","article-title":"Genetic analysis of a tetracycline resistance element from Clostridium difficile and its conjugal transfer to and from Bacillus subtilis","volume":"136","author":"Mullany","year":"1990","journal-title":"J Gen Microbiol"},{"key":"2023070504555327600_dkad170-B29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections\u2014United States","volume":"68","author":"Kourtis","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023070504555327600_dkad170-B30","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1592\/phco.26.12.1784","article-title":"Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists","volume":"26","author":"Huang","year":"2006","journal-title":"Pharmacotherapy"},{"key":"2023070504555327600_dkad170-B31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1086\/338403","article-title":"Thrombocytopenia associated with linezolid therapy","volume":"34","author":"Attassi","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2023070504555327600_dkad170-B32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01581-18","article-title":"Omadacycline gut microbiome exposure does not induce Clostridium difficile proliferation or toxin production in a model that simulates the proximal, medial, and distal human colon","volume":"63","author":"Moura","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/7\/1779\/50792691\/dkad170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/7\/1779\/50792691\/dkad170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T08:20:17Z","timestamp":1688545217000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/7\/1779\/7190216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,6]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad170","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,6,6]]}}}